Brickell Biotech Inc (OQ:BBI)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 5777 Central Ave Ste 102
BOULDER CO 80301-2870
Tel: N/A
IR: See website
Key People
Reginald L. Hardy
Chairman of the Board, Co-Founder
Robert B. Brown
Chief Executive Officer, Director
Andrew D. Sklawer
Co-Founder, Chief Operating Officer, Secretary
R. Michael Carruthers
Chief Financial Officer
Jose Breton
Chief Accounting Officer, Controller
David R. McAvoy
Chief Compliance Officer, General Counsel, Assistant Secretary
Deepak Chadha
Chief Research and Development Officer
Adam Scott Levy
Chief Business Officer
Business Overview
Brickell Biotech, Inc., formerly Vical Incorporated, is a clinical-stage pharmaceutical company that focuses on the development of therapeutics for the treatment of skin diseases. The Company's pipeline consists of molecular entities targeting the treatment of the indications, such as hyperhidrosis, cutaneous T-cell lymphoma, allergic contact dermatitis, psoriasis and androgenic alopecia. The Company's product candidates include BBI-3000, BBI-6000 and Sofpironium Bromide. Sofpironium Bromide is a topical soft anticholinergic for axillary hyperhidrosis. BBI-3000 is an oral rexinoid for cutaneous T-cell lymphoma. BBI-6000 is a retinoic acid-related orphan nuclear receptor gamma antagonist, which is develops for psoriasis.
Financial Overview
For the six months ended 30 June 2020, Brickell Biotech Inc revenues decreased 73% to $1.7M. Net loss applicable to common stockholders totaled $9.2M vs. income of $2.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects General and administrative - Balancing v increase of 68% to $4.8M (expense).
Employees: 15 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $1.51M as of Jun 30, 2020
Annual revenue (TTM): $3.51M as of Jun 30, 2020
EBITDA (TTM): -$21.29M as of Jun 30, 2020
Net annual income (TTM): -$24.95M as of Jun 30, 2020
Free cash flow (TTM): -$37.77M as of Jun 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 27,787,081 as of Aug 12, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.